State Street Corp. Updates Passive Stake in Enanta Pharma
Ticker: ENTA · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, pharmaceuticals
TL;DR
**State Street still holds Enanta Pharma stock, signaling ongoing institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended Schedule 13G/A on January 22, 2024, indicating its ownership of Enanta Pharmaceuticals Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued passive investment in the pharmaceutical company. This matters to investors because it confirms a large institutional holder's ongoing stake, which can signal confidence in the company's long-term prospects, though the specific percentage of ownership is not detailed in the provided text.
Why It Matters
This filing confirms State Street Corporation's continued passive investment in Enanta Pharmaceuticals, which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor and does not indicate any immediate significant risk or change in company fundamentals.
Analyst Insight
An investor should note that a major institution like State Street Corporation maintains a passive stake in Enanta Pharmaceuticals, suggesting continued confidence, but should also research the specific percentage of ownership and any changes from previous filings to gauge the strength of this signal.
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Enanta Pharmaceuticals Inc. (company) — the subject company whose stock is being reported
- 04-2456637 (number) — State Street Corporation's IRS Identification No.
- December 31, 2023 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, indicating a change or update to a previously reported passive ownership stake.
Who is the reporting person in this filing?
The reporting person is State Street Corporation, with IRS Identification No. 04-2456637, located at 1 Congress Street, Boston, MA.
What is the subject company whose securities are being reported?
The subject company is Enanta Pharmaceuticals Inc., a pharmaceutical preparations company with CIK 0001177648, located at 500 Arsenal Street, Watertown, MA.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the common stock of Enanta Pharmaceuticals Inc. is 29251M106.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding ENANTA PHARMACEUTICALS INC (ENTA).